Literature DB >> 14052974

PERIPHERAL NEUROPATHY FOLLOWING CHLOROQUINE THERAPY.

L R LOFTUS.   

Abstract

Four patients were observed who developed similar episodes of peripheral neuropathy following prolonged treatment with chloroquine phosphate. This previously unreported toxic reaction consisted of bilateral loss of knee and ankle reflexes and weakness of the quadriceps muscles. Gradual return to normal followed withdrawal of the chloroquine. Other toxic reactions to the drug are reviewed.

Entities:  

Keywords:  ARTHRITIS, RHEUMATOID; CHLOROQUINE; GERIATRICS; PERIPHERAL NERVE DISEASES; TOXICOLOGIC REPORT

Mesh:

Substances:

Year:  1963        PMID: 14052974      PMCID: PMC1921850     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  10 in total

1.  [Bilateral paralysis of the abducent nerve as cause of diplopia after the use of chloroquine].

Authors:  F KALSBEEK
Journal:  Ned Tijdschr Geneeskd       Date:  1960-07-23

2.  Corneal complication of chloroquine (aralen) phosphate therapy.

Authors:  R W ZELLER; D DEERING
Journal:  J Am Med Assoc       Date:  1958-12-27

3.  New allergic reaction to furaltadone.

Authors:  L R LOFTUS; A W WAGNER
Journal:  J Am Med Assoc       Date:  1960-05-28

4.  Retinopathy following chloroquine therapy.

Authors:  H E HOBBS; A SORSBY; A FREEDMAN
Journal:  Lancet       Date:  1959-10-03       Impact factor: 79.321

5.  The value of chloroquine in rheumatoid disease: a four-year study of continuous therapy.

Authors:  A W BAGNALL
Journal:  Can Med Assoc J       Date:  1957-08-01       Impact factor: 8.262

6.  The ocular complications of chloroquine therapy.

Authors:  H E HOBBS; C D CALNAN
Journal:  Lancet       Date:  1958-06-07       Impact factor: 79.321

7.  Treatment of lupus erythematosus with mepacrine.

Authors:  F PAGE
Journal:  Lancet       Date:  1951-10-27       Impact factor: 79.321

8.  Central scotomata following chloroquine therapy.

Authors:  H REED; A A CAMPBELL
Journal:  Can Med Assoc J       Date:  1962-01-27       Impact factor: 8.262

9.  OCULAR LESIONS AFTER TREATMENT WITH CHLOROQUINE.

Authors:  H E Hobbs; S P Eadie; F Somerville
Journal:  Br J Ophthalmol       Date:  1961-04       Impact factor: 4.638

10.  Bilateral macular degeneration associated with chloroquine therapy.

Authors:  R PENNER; K SOMERS
Journal:  Am J Ophthalmol       Date:  1962-09       Impact factor: 5.258

  10 in total
  8 in total

1.  Neuromyopathy associated with amodiaquine hydrochloride.

Authors:  R Wittes
Journal:  CMAJ       Date:  1987-10-01       Impact factor: 8.262

2.  Motor polyneuroapthy and nystagmus associated with chloroquine phosphate.

Authors:  J S Marks
Journal:  Postgrad Med J       Date:  1979-09       Impact factor: 2.401

3.  [Experimental lesions of the nervous and muscular systems due to chloroquine: models of various storage dystrophies (author's transl)].

Authors:  G W Klinghardt
Journal:  Acta Neuropathol       Date:  1974       Impact factor: 17.088

4.  [Tumor- and drug-induced cutaneous axonal dystrophy. An electronmicrocopy proof of multiple lamellated bodies].

Authors:  U Runne; C E Orfanos
Journal:  Arch Dermatol Res       Date:  1975-11-14       Impact factor: 3.017

5.  Adverse reactions to chloroquine and amodiaquine as used for malaria prophylaxis: a review of the literature.

Authors:  R Wittes
Journal:  Can Fam Physician       Date:  1987-11       Impact factor: 3.275

Review 6.  A clinical and economic review of disease-modifying antirheumatic drugs.

Authors:  S E Gabriel; D Coyle; L W Moreland
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

7.  Chloroquine and Hydroxychloroquine Myopathy: Clinical Spectrum and Treatment Outcomes.

Authors:  Elie Naddaf; Pritikanta Paul; Omar F AbouEzzeddine
Journal:  Front Neurol       Date:  2021-02-02       Impact factor: 4.003

Review 8.  Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities.

Authors:  Romain Muller
Journal:  Rheumatol Int       Date:  2021-04-24       Impact factor: 2.631

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.